47 In patients with overweight or obesity without diabetes, the Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) trial showed that tirzepatide 15 mg weekly led to a mean body weight reduction of 20.9% after 72 weeks of treatment, compared with 3.1% with placebo
Why did Wegovy (semaglutide) lower Covid-19 mortality
Author Contributions Acquisition, analysis, or interpretation of data: Hammad Khan, Shahab Khan, Khizer Hamza, Faiza Gul, Sana Atta Ullah Drafting of the manuscript: Hammad Khan, Azra Jabin, Zain Ullah Durrani, Faiza Gul, Sana Atta Ullah, Saleem Shah Supervision: Hammad Khan Concept and design: Azra Jabin, Zain Ullah Durrani, Fahad Dayam, Muhammad Yaseen, Saleem Shah Critical review of the manuscript for important intellectual content: Shahab Khan, Khizer Hamza, Fahad Dayam, Muhammad Yaseen, Saleem Shah References 1.Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes and non-alcoholic fatty liver diseasecurrent evidence
What does the clinical evidence actually show about milk thistle for liver health
Our plan will also incorporate dietary recommendations, exercise guidelines, and other lifestyle modifications to support your overall health and well-being
